A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells
| Autor: | Zhong Wang, Changhua Zhou, Ping He, Aifen Li, Li Li, Bin Dong, Jieyu Xing, Qing Li |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Bacterial expression medicine.drug_class Bispecific antibody Biophysics Biology Monoclonal antibody Applied Microbiology and Biotechnology 03 medical and health sciences 0302 clinical medicine Breast cancer Her2 Antigen Trastuzumab medicine Fab skin and connective tissue diseases neoplasms Single domain antibody medicine.disease Molecular biology Metastatic breast cancer 030104 developmental biology Single-domain antibody 030220 oncology & carcinogenesis Cancer cell biology.protein Original Article Antibody CD16 medicine.drug |
| Zdroj: | AMB Express |
| ISSN: | 2191-0855 |
| Popis: | Her2, which is frequently overexpressed in breast cancer, is one of the most studied tumor-associated antigens for cancer therapy. Anti-HER2 monoclonal antibody, trastuzumab, has achieved significant clinical benefits in metastatic breast cancer. In this study, we describe a novel bispecific antibody Her2-S-Fab targeting Her2 by linking a single domain anti-CD16 VHH to the trastuzumab Fab. The Her2-S-Fab antibody can be efficiently expressed and purified from Escherichia coli, and drive potent cancer cell killing in HER2-overexpressing cancer cells. In xenograft model, the Her2-S-Fab suppresses tumor growth in the presence of human immune cells. Our results suggest that the bispecific Her2-S-Fab may provide a valid alternative to Her2 positive cancer therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|